RxDoctor Payments Data

John Chaney

Psychiatric/Mental Health · Baton Rouge, LANPI 1134447816

Payments from drug & device makers

$2,231in general payments, 2019–2025

Across 112 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$406
  • AbbVie$326
  • Supernus Pharmaceuticals, Inc.$209
  • Otsuka America Pharmaceutical, Inc.$203
  • Neurocrine Biosciences, Inc.$178
  • Lundbeck LLC$162
  • plus $747 from 13 others

What the payments were for

  • Food & beverage$2,231100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,231 in reported general payments places this provider in the 65th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$926
Medicare patients
14
Services billed
14

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine22$138,918
Invega SustennaPaliperidone Palmitate29$104,148
PerserisRisperidone12$33,227
VraylarCariprazine Hcl14$19,088
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl50$16,766
TrintellixVortioxetine Hydrobromide16$10,153
RexultiBrexpiprazole13$8,574
Lurasidone Hcl44$7,071
Trazodone Hcl166$5,608
Aripiprazole148$4,105
Desvenlafaxine Succinate ErDesvenlafaxine Succinate73$3,513
Atomoxetine Hcl50$2,841
Quetiapine Fumarate266$2,837
Bupropion XlBupropion Hcl154$2,235
Haloperidol28$2,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$113$138,91822 claims
Johnson & JohnsonInvega Sustenna$73$104,14829 claims
Indivior Inc.Perseris$35$33,22712 claims
AbbVieVraylar$326$19,08814 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$91$10,15316 claims
Otsuka America Pharmaceutical, Inc.Rexulti$203$8,57413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →